For instance in a tumour setting, where antigen presentation occurs in the absence of strong innate activating signals, Treg can directly inhibit CD8+ T-cell-mediated cytolysis through TGF-β-dependent inhibition of degranulation [11], [12] but appear not to modulate effector differentiation. The gene discussed is CD8A; the disease is neoplasm.